Ebola Bundibugyo: WHO calls for 1.3 billion dollars for six months of response in Congo

The health picture that the morning did not cover concerns two twin epidemics with different outcomes. The World Health Organization has confirmed that the Ebola outbreak in Uganda is over, as the Director-General stated at the press briefing on September 2, 2026. In the Democratic Republic of Congo, where the outbreak had been confirmed in the same month, May 2026, transmission continues (GlobalSecurity.org; World Health Organization).

The agent is the Bundibugyo virus, one of the species of the ebolavirus genus. According to the WHO, the Congolese outbreak, detected in May, has expanded rapidly, in a context already marked by a humanitarian crisis: a remote and densely populated area, insecurity, strong population and trade movements.

The figure and its context

The government-led response plan for the Democratic Republic of Congo for the following six months requires 1.3 billion US dollars, a sum referring to the work of all partners involved, not to the organization alone. The Director-General has called on donors to increase and accelerate contributions, explicitly acknowledging that humanitarian funding is shrinking. The formula he used, as reported by the press briefing transcript, is: “The longer this takes, the higher the cost, in lives and resources” (transl. from English).

The WHO states that the response has already been scaled up but requires further strengthening with the support of the international community, and indicates that it is supporting the governments of the Democratic Republic of Congo and Uganda on surveillance, contact tracing, clinical management, supplies, community engagement and cross-border preparedness (briefing to Member States of September 1).

The medical tools issue

Here precision matters more than elsewhere. For the Bundibugyo species of ebolavirus there are no approved vaccines or specific treatments: the WHO states this. There is an approved vaccine against the Zaire ebolavirus, but — again according to the organization — it is not known whether it is effective against the Bundibugyo virus.

On September 1, 2026, the WHO published emergency guidance on the use of that vaccine during Bundibugyo virus outbreaks. This is a guidance document for health authorities, not a certification of effectiveness: the same source publishing the guidance declares uncertainty about the protective effect.

On the research front, the organization is working with partners to bring three candidate vaccines to efficacy studies in the Democratic Republic of Congo starting in October or November 2026. Overall, three vaccines and three therapies are under trial against the ongoing epidemic.

The limits of what has been published

On this part of the story, caveats must be stated, not implied. Efficacy studies on the three candidate vaccines have not yet begun: the WHO indicates their start for October or November 2026, so at present no results exist, and no efficacy data are available. The material consulted does not specify the trial phase of the three vaccines and three therapies, does not report the design of the planned studies — randomization, comparison group, enrollment criteria — nor the expected sample size.

The sources used here are not peer-reviewed publications: they are institutional communications from the WHO, that is, from the body coordinating the response and promoting the studies. No declaration of conflicts of interest regarding the trials appears in the documents available, and it is not indicated which manufacturers are supplying the products under trial.

Correlation must also be distinguished from causation: the end of the Ugandan epidemic is an outcome recorded by the WHO, not proof of the effectiveness of a single intervention. The material contains no analysis attributing that result to a specific measure.

The institutional framework

The public health emergency of international concern remains in effect. The Pan American Health Organization issued a note on May 17, 2026 on the emergency linked to the Bundibugyo virus in the Democratic Republic of Congo and Uganda and on the implications for the Americas (PAHO). On August 18, 2026, the second meeting of the International Health Regulations Emergency Committee on the Congolese epidemic was held.

What we don’t know

The material available does not contain an updated count of cases and deaths in the Democratic Republic of Congo, nor the share of the plan already funded. We do not know how much of the 1.3 billion requested has been committed, and without that figure the appeal to donors remains a figure of need, not a measured gap. The stated goal of the WHO for Congo is to replicate the Ugandan outcome by reducing the number of lives lost.